Literature DB >> 22549280

Ultrastructural scoring of skin biopsies for diagnosis of vascular Ehlers-Danlos syndrome.

Kim-Thanh Ong1, Henri Plauchu, Simone Peyrol, Elisabeth Roux, Elisabeth Errazuriz, Philippe Khau Van Kien, Brigitte Arbeille, Alain Gaulier, Gabriela Georgescou, Patrick Collignon, Dominique P Germain, Marie-Noëlle Gaveau, Jérôme Perdu, Stéphane Laurent, Patrick Bruneval, Pierre Boutouyrie.   

Abstract

Vascular Ehlers-Danlos syndrome (vEDS) results from a mutation in the gene encoding alpha-1, type III pro-collagen (COL3A1) and confers fragility to skin, ligament and vascular tissue. We tested the value of skin biopsy for diagnosis of vEDS through an ultrastructure scoring procedure. Study design was a multicentric, case-control, blinded trial consisting of two phases: phase 1 was to identify an ultra-structure score providing the best discriminative value for vEDS and phase 2 was to replicate this result in a different population. We enrolled 103 patients, 66 cases defined through the revised nosology for Ehlers-Danlos syndromes and 37 control subjects selected from patients referred for other pathologies. Ultrastructure of extracellular matrix was read by three to five experienced pathologists blinded for diagnosis. We used the receiver operating curves and logistic regression analysis for ranking ultrastructure scores. We created a detailed description of lesions observed in vEDS patients with 27 items (coded 0 or 1). In the phase 1 (17 cases and 20 controls), abnormal fibroblast shape, presence of lysosomes in the fibroblast and abnormal basal lamina were found to be independent discriminative items. Addition of these three items (defining an ultrastructure score) had the best diagnosis value (area under the curve (AUC) = 0.96). In the phase 2 (49 cases, 17 controls), ultrastructure score provided odds ratio of 9.76 (95 % CI 2.91-32.78), and AUC of 0.90. The ultrastructure score of skin biopsy has predictive value for the diagnosis of vEDS. Presence of two or more signs (either abnormal fibroblast, presence of lysosomes in the fibroblast or abnormal basal lamina) is very evocative of vEDS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22549280     DOI: 10.1007/s00428-012-1233-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  24 in total

Review 1.  Skin is a window on heritable disorders of connective tissue.

Authors:  K A Holbrook; P H Byers
Journal:  Am J Med Genet       Date:  1989-09

Review 2.  Procollagen trafficking, processing and fibrillogenesis.

Authors:  Elizabeth G Canty; Karl E Kadler
Journal:  J Cell Sci       Date:  2005-04-01       Impact factor: 5.285

3.  Mutations in the COL3A1 gene result in the Ehlers-Danlos syndrome type IV and alterations in the size and distribution of the major collagen fibrils of the dermis.

Authors:  L T Smith; U Schwarze; J Goldstein; P H Byers
Journal:  J Invest Dermatol       Date:  1997-03       Impact factor: 8.551

Review 4.  Molecular mechanisms of connective tissue abnormalities in the Ehlers-Danlos syndrome.

Authors:  P H Byers; G S Barsh; K A Holbrook
Journal:  Coll Relat Res       Date:  1981-09

5.  Ehlers-Danlos syndrome type IV: a multi-exon deletion in one of the two COL3A1 alleles affecting structure, stability, and processing of type III procollagen.

Authors:  A Superti-Furga; E Gugler; R Gitzelmann; B Steinmann
Journal:  J Biol Chem       Date:  1988-05-05       Impact factor: 5.157

6.  Ultrastructural study of the dermis in a case of type IV Ehlers-Danlos syndrome.

Authors:  L Vitellaro-Zuccarello; F Cheli; R Esposito; A Bairati
Journal:  J Submicrosc Cytol       Date:  1985-10

7.  Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.

Authors:  Kim-Thanh Ong; Jérôme Perdu; Julie De Backer; Erwan Bozec; Patrick Collignon; Joseph Emmerich; Anne-Laure Fauret; Jean-Noël Fiessinger; Dominique P Germain; Gabriella Georgesco; Jean-Sebastien Hulot; Anne De Paepe; Henri Plauchu; Xavier Jeunemaitre; Stéphane Laurent; Pierre Boutouyrie
Journal:  Lancet       Date:  2010-09-07       Impact factor: 79.321

8.  Heterozygosity for a large deletion in the alpha 2(I) collagen gene has a dramatic effect on type I collagen secretion and produces perinatal lethal osteogenesis imperfecta.

Authors:  M C Willing; D H Cohn; B Starman; K A Holbrook; C R Greenberg; P H Byers
Journal:  J Biol Chem       Date:  1988-06-15       Impact factor: 5.157

9.  Clinical and ultrastructural heterogeneity of type IV Ehlers-Danlos syndrome.

Authors:  P H Byers; K A Holbrook; B McGillivray; P M MacLeod; R B Lowry
Journal:  Hum Genet       Date:  1979-03-12       Impact factor: 4.132

10.  Patients with Ehlers-Danlos syndrome type IV lack type III collagen.

Authors:  F M Pope; G R Martin; J R Lichtenstein; R Penttinen; B Gerson; D W Rowe; V A McKusick
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

View more
  2 in total

Review 1.  The Role of Cell Adhesion and Cytoskeleton Dynamics in the Pathogenesis of the Ehlers-Danlos Syndromes and Hypermobility Spectrum Disorders.

Authors:  Sabeeha Malek; Darius V Köster
Journal:  Front Cell Dev Biol       Date:  2021-04-21

Review 2.  The Relevance of Skin Biopsies in General Internal Medicine: Facts and Myths.

Authors:  Sophie Bailleux; Patrick Collins; Arjen F Nikkels
Journal:  Dermatol Ther (Heidelb)       Date:  2022-04-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.